chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Vascular imaging, Venogram abnormal, Vitamin B12 normal
Clinical narrative: Pt is a 75 y.o. male with a history of dementia, CAD, HFrEF, HTN, sick sinus syndrome s/p PPM and recent COVID-19 who presented to medical facility with encephalopathy and a fever. Confirmed COVID-19 positive, met sepsis criteria. Found to have acute dural sinus thrombosis, AKI, hypernatremia. He was transferred to hospital 11/10/2022 for neurology evaluation. Course complicated by acute cholecystitis and need for PCT. Course further complicated by poor PO intake, palliative followed and eventually discharged   1. Acute Dural Sinus Thrombosis: CTH at hospital shows diffuse cerebral venous sinus thrombosis. Hospital CTH unchanged CVST, no intracranial hemorrhage, diffuse ventriculomegaly. CT venogram brain 11/12/22 with stable dural venous sinus thrombosis, possible right frontal centrum semiovale stroke. IV heparin infusion and transition to Pradaxa or Warfarin.  Transitioned heparin gtt to pradaxa 11/20/22. Neurology followed.  2. Acute cholecystitis: Abd pain complaints. CT abd 11/13/22 with acute cholecystitis. Positive HIDA 11/14/22. S/p PCT with VIR 11/15/22, culture NGTD. S/p IV Zosyn. GS followed, OP follow up. VIR recommended PCT exchanges every 2-3 months. 3. Malnutrition: patient with poor PO intake. RD followed. Discussed with wife 11/18/22, would be ok with PEG if intake does not improve. PO intake improved 4. Ventriculomegaly: noted on CTV 11/12/22, out of proportion with sulci, possibly related to advanced dementia vs normal pressure hydrocephalus. Neurology followed.   5. Acute Metabolic on Chronic Encephalopathy: Hx reportedly "advanced" dementia with agiation at baseline. Patient lethargic, weak, and AAOx1 on admit. Admit alcohol, UDS, B12/folate, TSH, RPR, HIV all unremarkable, Ammonia 48. Continued home mirtazapine, quetiapine. Palliative care followed, family wants time limited trial at SNF. Improved 6. Sepsis in setting COVID-19: Presented to hospital with T101.3, tachypnea, tachycardia. Positive for COVID on home test, unknown date. Secondary to acute cholecystitis as above. Hospital resp viral PCR: COVID-19 positive. Admit CXR, UA unremarkable, blood cultures NGTD. Resolved with IV abx as above. 7. AKI on CKD-2: Baseline Cr 0.9-1.2. OLH Cr 2.06, improved with IVF. However, Cr back to 1.6 11/15/22. Improved 8. Chronic HFrEF: Per history. TTE 4/6/22 with EF 44%, moderate AV sclerosis and mild AS, abnormal septal and apical WMA due to conduction abnormality. IVF given above.  9. SSS: s/p PPM.  10. CAD: LHC 2/2021 with DES placed for 90% RCA stenosis. Continued home aspirin, statin.  11. Code Status: DNR-CCA, DNI. Palliative followed, family wants time limited trial at SNF.
Age: 25.0
Sex: M
Vaccine: COVID19-2
Symptoms: Influenza like illness, Injection site erythema
Clinical narrative: Redness of injection site, flu-like symptoms
Age: 73.0
Sex: M
Vaccine: COVID19-2
Symptoms: Nasopharyngitis, SARS-CoV-2 test
Clinical narrative: Cold symptoms starting 12/18/2022
Age: 18.0
Sex: F
Vaccine: COVID19-2, FLUC4
Symptoms: Dizziness, Fall, Loss of consciousness, Nausea, Pallor
Clinical narrative: patient came in for her covid booster (pfizer bivalent) and flu shot. after administration pt was sitting on  the blood pressure machine; a few minutes later the patient fell to the floor. Grandma threw her purse under her head to soften her fall. I ran out to the patient and she was already coming to. She was very pale, nauseous and light headed. we got her a coke, water and some chocolate. pt sat for 15-20 minutes on the ground. then we helped her to a wheelchair. She sat for a while longer until she felt better
Age: 70.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Autoimmune disorder, Back pain, Blood test abnormal, Immediate post-injection reaction
Clinical narrative: In October 2021 after dose 3 I began noticing reoccurring joint and muscle aches in lower back shoulder and neck area.  I had made multiple visits with my chiropractor and was unable to resolve the pain.  At some point I saw my GP and prescribed a pain killer that was not effective.  In late December and January, the pain was almost intolerable.  There were no rheumatologists available for a quick appointment.  I was able to see another rheumatologist doctor in late February.  I was immediately put on high dose of prednisone and it helped immediately with the pain.  I have continued taking this and have changed dosages over time.  I am told that I have Polymyalgia, auto-immune disease, for 5 more years.  The onset of this began immediately after my Pfizer vaccine.
Age: 70.0
Sex: M
Vaccine: COVID19
Symptoms: Myalgia
Clinical narrative: In October 2021 after dose 3 I began noticing reoccurring joint and muscle aches in lower back shoulder and neck area.  I had made multiple visits with my chiropractor and was unable to resolve the pain.  At some point I saw my GP and prescribed a pain killer that was not effective.  In late December and January, the pain was almost intolerable.  There were no rheumatologists available for a quick appointment.  I was able to see another rheumatologist doctor in late February.  I was immediately put on high dose of prednisone and it helped immediately with the pain.  I have continued taking this and have changed dosages over time.  I am told that I have Polymyalgia, auto-immune disease, for 5 more years.  The onset of this began immediately after my Pfizer vaccine.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Blood culture negative, COVID-19, Cancer pain, Computerised tomogram abdomen abnormal
Clinical narrative: Patient is a 69 y.o. female admitted to the hospital on 11/18/2022 for weakness and fatigue.  Patient found with COVID and with abnormal urinalysis.  She improved with Zosyn then transition to Keflex on discharge.  Patient stable for discharge home on 11/23/2022.   Discharge Diagnosis and Associated Hospital Course   Severe sepsis COVID-19 infection -Likely secondary to COVID, possibly UTI.  Patient's husband with COVID infection. -COVID-positive 11/19/2022.  UA consistent with UTI; urine culture not sent.  Blood cultures NGTD. -CT C/A/P with possible colitis. -De-escalate Zosyn to Keflex for total 7-day course (last dose 11/25/2022).  Continue supportive care; and isolation 11/30/2022.  If new oxygen requirement, start steroids.  Continue home midodrine.   Acute on chronic hypotension -Possibly dehydration, consider sepsis.  Recently started on midodrine during last hospitalization September 2022 for septic shock.  Home BP 70s/40s. -S/p 1 L IVF in ED and albumin 25 g x 4 doses. -Continue home midodrine.   Fall from standing -Unwitnessed fall occurred while inpatient on 11/20/2022.  XR pelvis and CT head nonacute. -PT/OT consulted.  Continue fall precautions.   Metastatic pancreatic cancer Cancer related pain -Known history with mets to lung and abdomen, s/p Whipple July 2021, on palliative chemo.  Follows with Dr.  -Continue Oxley PRN, long-acting morphine.  Follow-up with Dr. outpatient.   History of PE -Diagnosed October 2021.  Continue home Eliquis.   Chronic anemia -Likely secondary to malignancy and chemotherapy. Hgb stable. -Follow-up outpatient.   Elevated troponin -Likely demand ischemia.  Troponin 71, delta negative.  EKG nonischemic.  TTE unchanged. -No further work-up Hypothyroidism -Continue home Synthroid.   Anxiety and depression -Continue home Effexor.   GERD -Continue PPI.   Malnutrition -In the setting of malignancy, POA. -Encourage oral intake.  Continue home dronabinol.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Computerised tomogram head normal, Computerised tomogram thorax, Echocardiogram, Electrocardiogram normal, Exposure to SARS-CoV-2
Clinical narrative: Patient is a 69 y.o. female admitted to the hospital on 11/18/2022 for weakness and fatigue.  Patient found with COVID and with abnormal urinalysis.  She improved with Zosyn then transition to Keflex on discharge.  Patient stable for discharge home on 11/23/2022.   Discharge Diagnosis and Associated Hospital Course   Severe sepsis COVID-19 infection -Likely secondary to COVID, possibly UTI.  Patient's husband with COVID infection. -COVID-positive 11/19/2022.  UA consistent with UTI; urine culture not sent.  Blood cultures NGTD. -CT C/A/P with possible colitis. -De-escalate Zosyn to Keflex for total 7-day course (last dose 11/25/2022).  Continue supportive care; and isolation 11/30/2022.  If new oxygen requirement, start steroids.  Continue home midodrine.   Acute on chronic hypotension -Possibly dehydration, consider sepsis.  Recently started on midodrine during last hospitalization September 2022 for septic shock.  Home BP 70s/40s. -S/p 1 L IVF in ED and albumin 25 g x 4 doses. -Continue home midodrine.   Fall from standing -Unwitnessed fall occurred while inpatient on 11/20/2022.  XR pelvis and CT head nonacute. -PT/OT consulted.  Continue fall precautions.   Metastatic pancreatic cancer Cancer related pain -Known history with mets to lung and abdomen, s/p Whipple July 2021, on palliative chemo.  Follows with Dr.  -Continue Oxley PRN, long-acting morphine.  Follow-up with Dr. outpatient.   History of PE -Diagnosed October 2021.  Continue home Eliquis.   Chronic anemia -Likely secondary to malignancy and chemotherapy. Hgb stable. -Follow-up outpatient.   Elevated troponin -Likely demand ischemia.  Troponin 71, delta negative.  EKG nonischemic.  TTE unchanged. -No further work-up Hypothyroidism -Continue home Synthroid.   Anxiety and depression -Continue home Effexor.   GERD -Continue PPI.   Malnutrition -In the setting of malignancy, POA. -Encourage oral intake.  Continue home dronabinol.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Fall, Fatigue, Haemoglobin normal, Hypotension, Myocardial ischaemia
Clinical narrative: Patient is a 69 y.o. female admitted to the hospital on 11/18/2022 for weakness and fatigue.  Patient found with COVID and with abnormal urinalysis.  She improved with Zosyn then transition to Keflex on discharge.  Patient stable for discharge home on 11/23/2022.   Discharge Diagnosis and Associated Hospital Course   Severe sepsis COVID-19 infection -Likely secondary to COVID, possibly UTI.  Patient's husband with COVID infection. -COVID-positive 11/19/2022.  UA consistent with UTI; urine culture not sent.  Blood cultures NGTD. -CT C/A/P with possible colitis. -De-escalate Zosyn to Keflex for total 7-day course (last dose 11/25/2022).  Continue supportive care; and isolation 11/30/2022.  If new oxygen requirement, start steroids.  Continue home midodrine.   Acute on chronic hypotension -Possibly dehydration, consider sepsis.  Recently started on midodrine during last hospitalization September 2022 for septic shock.  Home BP 70s/40s. -S/p 1 L IVF in ED and albumin 25 g x 4 doses. -Continue home midodrine.   Fall from standing -Unwitnessed fall occurred while inpatient on 11/20/2022.  XR pelvis and CT head nonacute. -PT/OT consulted.  Continue fall precautions.   Metastatic pancreatic cancer Cancer related pain -Known history with mets to lung and abdomen, s/p Whipple July 2021, on palliative chemo.  Follows with Dr.  -Continue Oxley PRN, long-acting morphine.  Follow-up with Dr. outpatient.   History of PE -Diagnosed October 2021.  Continue home Eliquis.   Chronic anemia -Likely secondary to malignancy and chemotherapy. Hgb stable. -Follow-up outpatient.   Elevated troponin -Likely demand ischemia.  Troponin 71, delta negative.  EKG nonischemic.  TTE unchanged. -No further work-up Hypothyroidism -Continue home Synthroid.   Anxiety and depression -Continue home Effexor.   GERD -Continue PPI.   Malnutrition -In the setting of malignancy, POA. -Encourage oral intake.  Continue home dronabinol.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: SARS-CoV-2 test positive, Sepsis, Septic shock, Troponin increased, Urinary tract infection
Clinical narrative: Patient is a 69 y.o. female admitted to the hospital on 11/18/2022 for weakness and fatigue.  Patient found with COVID and with abnormal urinalysis.  She improved with Zosyn then transition to Keflex on discharge.  Patient stable for discharge home on 11/23/2022.   Discharge Diagnosis and Associated Hospital Course   Severe sepsis COVID-19 infection -Likely secondary to COVID, possibly UTI.  Patient's husband with COVID infection. -COVID-positive 11/19/2022.  UA consistent with UTI; urine culture not sent.  Blood cultures NGTD. -CT C/A/P with possible colitis. -De-escalate Zosyn to Keflex for total 7-day course (last dose 11/25/2022).  Continue supportive care; and isolation 11/30/2022.  If new oxygen requirement, start steroids.  Continue home midodrine.   Acute on chronic hypotension -Possibly dehydration, consider sepsis.  Recently started on midodrine during last hospitalization September 2022 for septic shock.  Home BP 70s/40s. -S/p 1 L IVF in ED and albumin 25 g x 4 doses. -Continue home midodrine.   Fall from standing -Unwitnessed fall occurred while inpatient on 11/20/2022.  XR pelvis and CT head nonacute. -PT/OT consulted.  Continue fall precautions.   Metastatic pancreatic cancer Cancer related pain -Known history with mets to lung and abdomen, s/p Whipple July 2021, on palliative chemo.  Follows with Dr.  -Continue Oxley PRN, long-acting morphine.  Follow-up with Dr. outpatient.   History of PE -Diagnosed October 2021.  Continue home Eliquis.   Chronic anemia -Likely secondary to malignancy and chemotherapy. Hgb stable. -Follow-up outpatient.   Elevated troponin -Likely demand ischemia.  Troponin 71, delta negative.  EKG nonischemic.  TTE unchanged. -No further work-up Hypothyroidism -Continue home Synthroid.   Anxiety and depression -Continue home Effexor.   GERD -Continue PPI.   Malnutrition -In the setting of malignancy, POA. -Encourage oral intake.  Continue home dronabinol.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Urine analysis abnormal, X-ray of pelvis and hip normal
Clinical narrative: Patient is a 69 y.o. female admitted to the hospital on 11/18/2022 for weakness and fatigue.  Patient found with COVID and with abnormal urinalysis.  She improved with Zosyn then transition to Keflex on discharge.  Patient stable for discharge home on 11/23/2022.   Discharge Diagnosis and Associated Hospital Course   Severe sepsis COVID-19 infection -Likely secondary to COVID, possibly UTI.  Patient's husband with COVID infection. -COVID-positive 11/19/2022.  UA consistent with UTI; urine culture not sent.  Blood cultures NGTD. -CT C/A/P with possible colitis. -De-escalate Zosyn to Keflex for total 7-day course (last dose 11/25/2022).  Continue supportive care; and isolation 11/30/2022.  If new oxygen requirement, start steroids.  Continue home midodrine.   Acute on chronic hypotension -Possibly dehydration, consider sepsis.  Recently started on midodrine during last hospitalization September 2022 for septic shock.  Home BP 70s/40s. -S/p 1 L IVF in ED and albumin 25 g x 4 doses. -Continue home midodrine.   Fall from standing -Unwitnessed fall occurred while inpatient on 11/20/2022.  XR pelvis and CT head nonacute. -PT/OT consulted.  Continue fall precautions.   Metastatic pancreatic cancer Cancer related pain -Known history with mets to lung and abdomen, s/p Whipple July 2021, on palliative chemo.  Follows with Dr.  -Continue Oxley PRN, long-acting morphine.  Follow-up with Dr. outpatient.   History of PE -Diagnosed October 2021.  Continue home Eliquis.   Chronic anemia -Likely secondary to malignancy and chemotherapy. Hgb stable. -Follow-up outpatient.   Elevated troponin -Likely demand ischemia.  Troponin 71, delta negative.  EKG nonischemic.  TTE unchanged. -No further work-up Hypothyroidism -Continue home Synthroid.   Anxiety and depression -Continue home Effexor.   GERD -Continue PPI.   Malnutrition -In the setting of malignancy, POA. -Encourage oral intake.  Continue home dronabinol.
Age: 3.0
Sex: M
Vaccine: DTAP, FLU4, HEPA
Symptoms: Abdominal pain, Blister, Erythema, Expired product administered, Incorrect dose administered
Clinical narrative: This patient was inadvertently administered an adult dose of havrix instead of the pediatric dose, so essentially got a double dose of vaccine.  The vaccine he received had expired on 12/15/22 so a week prior to administration.  The patient was examined by me.  Advised Mom of the erroneous administration of the vaccine and things to look out for.  The morning after vaccine received, parent reported a purple blister on the toe and a red line going from injection site to the toe.  Also reported fever and abdominal pain.  On call provider recommended ED eval.  Obviously current symptoms may be unrelated.
Age: 3.0
Sex: M
Vaccine: DTAP, FLU4, HEPA
Symptoms: Injection site erythema, Pyrexia
Clinical narrative: This patient was inadvertently administered an adult dose of havrix instead of the pediatric dose, so essentially got a double dose of vaccine.  The vaccine he received had expired on 12/15/22 so a week prior to administration.  The patient was examined by me.  Advised Mom of the erroneous administration of the vaccine and things to look out for.  The morning after vaccine received, parent reported a purple blister on the toe and a red line going from injection site to the toe.  Also reported fever and abdominal pain.  On call provider recommended ED eval.  Obviously current symptoms may be unrelated.
Age: 68.0
Sex: F
Vaccine: FLU4
Symptoms: Joint range of motion decreased, Mobility decreased, Pain in extremity, Peripheral swelling, Sleep disorder
Clinical narrative: Left arm swollen, sore and movement limited within hours after receiving vaccine.  Soreness, severe limitations on ability to lift arm and limitations on range of motion increased over the days and weeks.  Pain was most prominent at night and disrupted sleep.
Age: 68.0
Sex: F
Vaccine: FLU4
Symptoms: X-ray
Clinical narrative: Left arm swollen, sore and movement limited within hours after receiving vaccine.  Soreness, severe limitations on ability to lift arm and limitations on range of motion increased over the days and weeks.  Pain was most prominent at night and disrupted sleep.
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Atrial fibrillation, COVID-19, COVID-19 pneumonia, Chest X-ray abnormal, Chronic obstructive pulmonary disease
Clinical narrative: Assessment and Plan Patient is a 65 y.o. male patient of CNP with history of COPD, DM Type 2, obesity presented to Hospital with SOB, subsequently found to have COVID-19 infection   COVID PNA CXR: Mild patchy opacities within the lower chest Vaccinated with J&J Symptom onset: 11/09/2022 Tested positive: 11/11/2022 Baseline O2 requirement: 3L Current O2 requirement: 4L Anticipated end of isolation: 11/21/2022 On solumedrol due to COPD exacerbation, transition to oral prednisone, plan long taper 40 mg x 1 week, 30 mg x 1 week, 20 mg x 1 week, 10 mg x 1 week Completed PO Azithromycin during hospitalization due to COPD with increased sputum production   COPD Exacerbation Continue steroid and albuterol Had increased sputum production on presentation, completed course of azithromycin during hospitalization Continue supplemental O2, wean as tolerated   Paroxysmal A Fib with RVR Likely due to above Continue rate control with BB Resume Eliquis  Chronic heart failure with preserved ejection fraction Previous echo (5/13/2021) LVEF 50% ±5% Continue oral furosemide, BB, ACEi   Chronic Hypoxic Respiratory Failure Uses 3L of O2 at baseline, currently on 4 L Continue to maintain saturation >90%   DM Type 2 with Hyperglycemia Chronic Insulin use Continue ISS Lantus increased due to hyperglycemia from steroid use   OSA/OHS Morbid Obesity Resume BIPAP   Chronic Pain syndrome Resume Norco   BPH with Chronic indwelling foley  Last changed a week ago Continue to monitor
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Condition aggravated, Dyspnoea, Lung opacity, SARS-CoV-2 test positive, Sputum increased
Clinical narrative: Assessment and Plan Patient is a 65 y.o. male patient of CNP with history of COPD, DM Type 2, obesity presented to Hospital with SOB, subsequently found to have COVID-19 infection   COVID PNA CXR: Mild patchy opacities within the lower chest Vaccinated with J&J Symptom onset: 11/09/2022 Tested positive: 11/11/2022 Baseline O2 requirement: 3L Current O2 requirement: 4L Anticipated end of isolation: 11/21/2022 On solumedrol due to COPD exacerbation, transition to oral prednisone, plan long taper 40 mg x 1 week, 30 mg x 1 week, 20 mg x 1 week, 10 mg x 1 week Completed PO Azithromycin during hospitalization due to COPD with increased sputum production   COPD Exacerbation Continue steroid and albuterol Had increased sputum production on presentation, completed course of azithromycin during hospitalization Continue supplemental O2, wean as tolerated   Paroxysmal A Fib with RVR Likely due to above Continue rate control with BB Resume Eliquis  Chronic heart failure with preserved ejection fraction Previous echo (5/13/2021) LVEF 50% ±5% Continue oral furosemide, BB, ACEi   Chronic Hypoxic Respiratory Failure Uses 3L of O2 at baseline, currently on 4 L Continue to maintain saturation >90%   DM Type 2 with Hyperglycemia Chronic Insulin use Continue ISS Lantus increased due to hyperglycemia from steroid use   OSA/OHS Morbid Obesity Resume BIPAP   Chronic Pain syndrome Resume Norco   BPH with Chronic indwelling foley  Last changed a week ago Continue to monitor
Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Blood magnesium decreased, Blood sodium decreased, Blood test, Haemoglobin decreased, Hypotension
Clinical narrative: Low sodium; low magnesium; low blood pressure; low hemoglobin
Age: 83.0
Sex: M
Vaccine: COVID19-2
Symptoms: Acute respiratory failure, Anaemia, COVID-19, Chest X-ray normal, Chronic obstructive pulmonary disease
Clinical narrative: Assessment and Plan   Patient is a 83 y.o. male patient of DO with history of alternating esotropia, anemia, A. fib, BPH, cardiomyopathy, COPD, GERD, hypertension, hyperlipidemia, hypothyroidism, OA, valvular disease presented to Hospital with shortness of breath.   Acute hypoxia with respiratory failure Acute COPD exacerbation Secondary to COVID-19 infection Cough for 4 days, shortness of breath started today Evaluate for home O2 Discharge on decadron and azithromycin   Covid-19 Virus Infection Date of onset of symptoms: 11/20/22 Symptoms present on admission: Cough and shortness of breath Date of covid positive test: 11/24/22 Vaccination status: vaccinated Imaging: CXR-nonacute Oxygen requirements on admission: 2 L Current oxygen requirements: 2L Medical therapy: remdesivir, steroids, and zithromax Consultants following: None Anticipated special isolation end date: 11/30/22 Inflammatory labs WNL Discharge home with oxygen   Multiple myeloma Diagnosed July 2022 Follows with Dr. Continue home Revmilid, acyclovir, Bactrim   Thrombocytopenia Likely related to multiple myeloma and COVID infection No gross bleeding Monitor CBC Count now 84 Follow up outpatient with oncology   Chronic anemia Hgb 12.9 Baseline around 13 No gross bleeding Monitor CBC Atrial fibrillation Continue home Cardizem, metoprolol and Coumadin, ASA INR 2.5 Goal INR 2-3     Hypothyroidism Continue home Synthroid   Hyperlipidemia Continue home statin   BPH Continue home dutasteride   Hypertension Mild hypertension on admission Continue home metoprolol, Lasix   Tobacco abuse Advised on smoking cessation
Age: 83.0
Sex: M
Vaccine: COVID19-2
Symptoms: Condition aggravated, Cough, Dyspnoea, Full blood count, Haemoglobin decreased
Clinical narrative: Assessment and Plan   Patient is a 83 y.o. male patient of DO with history of alternating esotropia, anemia, A. fib, BPH, cardiomyopathy, COPD, GERD, hypertension, hyperlipidemia, hypothyroidism, OA, valvular disease presented to Hospital with shortness of breath.   Acute hypoxia with respiratory failure Acute COPD exacerbation Secondary to COVID-19 infection Cough for 4 days, shortness of breath started today Evaluate for home O2 Discharge on decadron and azithromycin   Covid-19 Virus Infection Date of onset of symptoms: 11/20/22 Symptoms present on admission: Cough and shortness of breath Date of covid positive test: 11/24/22 Vaccination status: vaccinated Imaging: CXR-nonacute Oxygen requirements on admission: 2 L Current oxygen requirements: 2L Medical therapy: remdesivir, steroids, and zithromax Consultants following: None Anticipated special isolation end date: 11/30/22 Inflammatory labs WNL Discharge home with oxygen   Multiple myeloma Diagnosed July 2022 Follows with Dr. Continue home Revmilid, acyclovir, Bactrim   Thrombocytopenia Likely related to multiple myeloma and COVID infection No gross bleeding Monitor CBC Count now 84 Follow up outpatient with oncology   Chronic anemia Hgb 12.9 Baseline around 13 No gross bleeding Monitor CBC Atrial fibrillation Continue home Cardizem, metoprolol and Coumadin, ASA INR 2.5 Goal INR 2-3     Hypothyroidism Continue home Synthroid   Hyperlipidemia Continue home statin   BPH Continue home dutasteride   Hypertension Mild hypertension on admission Continue home metoprolol, Lasix   Tobacco abuse Advised on smoking cessation
Age: 83.0
Sex: M
Vaccine: COVID19-2
Symptoms: Hypertension, Inflammatory marker test, International normalised ratio increased, Malaise, SARS-CoV-2 test positive
Clinical narrative: Assessment and Plan   Patient is a 83 y.o. male patient of DO with history of alternating esotropia, anemia, A. fib, BPH, cardiomyopathy, COPD, GERD, hypertension, hyperlipidemia, hypothyroidism, OA, valvular disease presented to Hospital with shortness of breath.   Acute hypoxia with respiratory failure Acute COPD exacerbation Secondary to COVID-19 infection Cough for 4 days, shortness of breath started today Evaluate for home O2 Discharge on decadron and azithromycin   Covid-19 Virus Infection Date of onset of symptoms: 11/20/22 Symptoms present on admission: Cough and shortness of breath Date of covid positive test: 11/24/22 Vaccination status: vaccinated Imaging: CXR-nonacute Oxygen requirements on admission: 2 L Current oxygen requirements: 2L Medical therapy: remdesivir, steroids, and zithromax Consultants following: None Anticipated special isolation end date: 11/30/22 Inflammatory labs WNL Discharge home with oxygen   Multiple myeloma Diagnosed July 2022 Follows with Dr. Continue home Revmilid, acyclovir, Bactrim   Thrombocytopenia Likely related to multiple myeloma and COVID infection No gross bleeding Monitor CBC Count now 84 Follow up outpatient with oncology   Chronic anemia Hgb 12.9 Baseline around 13 No gross bleeding Monitor CBC Atrial fibrillation Continue home Cardizem, metoprolol and Coumadin, ASA INR 2.5 Goal INR 2-3     Hypothyroidism Continue home Synthroid   Hyperlipidemia Continue home statin   BPH Continue home dutasteride   Hypertension Mild hypertension on admission Continue home metoprolol, Lasix   Tobacco abuse Advised on smoking cessation
Age: 83.0
Sex: M
Vaccine: COVID19-2
Symptoms: Thrombocytopenia
Clinical narrative: Assessment and Plan   Patient is a 83 y.o. male patient of DO with history of alternating esotropia, anemia, A. fib, BPH, cardiomyopathy, COPD, GERD, hypertension, hyperlipidemia, hypothyroidism, OA, valvular disease presented to Hospital with shortness of breath.   Acute hypoxia with respiratory failure Acute COPD exacerbation Secondary to COVID-19 infection Cough for 4 days, shortness of breath started today Evaluate for home O2 Discharge on decadron and azithromycin   Covid-19 Virus Infection Date of onset of symptoms: 11/20/22 Symptoms present on admission: Cough and shortness of breath Date of covid positive test: 11/24/22 Vaccination status: vaccinated Imaging: CXR-nonacute Oxygen requirements on admission: 2 L Current oxygen requirements: 2L Medical therapy: remdesivir, steroids, and zithromax Consultants following: None Anticipated special isolation end date: 11/30/22 Inflammatory labs WNL Discharge home with oxygen   Multiple myeloma Diagnosed July 2022 Follows with Dr. Continue home Revmilid, acyclovir, Bactrim   Thrombocytopenia Likely related to multiple myeloma and COVID infection No gross bleeding Monitor CBC Count now 84 Follow up outpatient with oncology   Chronic anemia Hgb 12.9 Baseline around 13 No gross bleeding Monitor CBC Atrial fibrillation Continue home Cardizem, metoprolol and Coumadin, ASA INR 2.5 Goal INR 2-3     Hypothyroidism Continue home Synthroid   Hyperlipidemia Continue home statin   BPH Continue home dutasteride   Hypertension Mild hypertension on admission Continue home metoprolol, Lasix   Tobacco abuse Advised on smoking cessation
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Headache, Injection site pain, Neck pain, Pain of skin
Clinical narrative: Shoulder Pain to the level 10 at onset.  Burning at injection site.  Then pain extending up the neck and affecting the trigeminal nerve giving pain over the entire scalp.   For three months surface headache varying between pain levels 5 to 8.  Now at six months, headache pain varying between 3 to 5 with an occasional pain to 8. Consulted an orthopaedic doctor for a shoulder xray, which showed nothing visable.  Consulted a neurologist who explained the trigeminal nerve involvement.  Tried prednisone.  No affect.  Tried 4 accupuncture treatments with an MD.  No effect.  Can still feel the shoulder pain and a cuff of burning at the injection site.  Use Aleve occassionally when going somewhere important.
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Trigeminal nerve disorder, X-ray limb normal
Clinical narrative: Shoulder Pain to the level 10 at onset.  Burning at injection site.  Then pain extending up the neck and affecting the trigeminal nerve giving pain over the entire scalp.   For three months surface headache varying between pain levels 5 to 8.  Now at six months, headache pain varying between 3 to 5 with an occasional pain to 8. Consulted an orthopaedic doctor for a shoulder xray, which showed nothing visable.  Consulted a neurologist who explained the trigeminal nerve involvement.  Tried prednisone.  No affect.  Tried 4 accupuncture treatments with an MD.  No effect.  Can still feel the shoulder pain and a cuff of burning at the injection site.  Use Aleve occassionally when going somewhere important.
Age: 58.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19-2
Symptoms: COVID-19, Cough, Fatigue, Oropharyngeal pain, SARS-CoV-2 test positive
Clinical narrative: Tested positive for COVID-19 on November 10, 2022 using a home test.  This was after serving as an election clerk for 8 hours on Election Day with no mask. Normally, I wear a mask due to being immunosupressed due to taking Enbrel but didn't wear a mask that day.  Symptoms were not too bad - slight sore throat, slight fatigue, sinus congestion, cough Started Paxlovid on November 12, 2022
Age: 58.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19-2
Symptoms: Sinus congestion
Clinical narrative: Tested positive for COVID-19 on November 10, 2022 using a home test.  This was after serving as an election clerk for 8 hours on Election Day with no mask. Normally, I wear a mask due to being immunosupressed due to taking Enbrel but didn't wear a mask that day.  Symptoms were not too bad - slight sore throat, slight fatigue, sinus congestion, cough Started Paxlovid on November 12, 2022
Age: 71.0
Sex: M
Vaccine: COVID19-2
Symptoms: COVID-19, Diarrhoea, Fatigue, Headache, Oropharyngeal pain
Clinical narrative: On December 15, 2022, I woke up extremely fatigued with a sore throat, headache, cough and severe diarrhea.  I tested positive for COVID-19 with a home test.  These symptoms lasted for 4 days.  My cough was productive with a lot of phlegm; however, it was intermittent.  I took Theraflu, Mucinex and Robitussin.  On day 5 my symptoms seemed to lesson quite a bit.  As of today, I am still fatigued and have a slight, intermittent cough.
Age: 71.0
Sex: M
Vaccine: COVID19-2
Symptoms: Productive cough, SARS-CoV-2 test positive
Clinical narrative: On December 15, 2022, I woke up extremely fatigued with a sore throat, headache, cough and severe diarrhea.  I tested positive for COVID-19 with a home test.  These symptoms lasted for 4 days.  My cough was productive with a lot of phlegm; however, it was intermittent.  I took Theraflu, Mucinex and Robitussin.  On day 5 my symptoms seemed to lesson quite a bit.  As of today, I am still fatigued and have a slight, intermittent cough.
Age: 79.0
Sex: F
Vaccine: COVID19
Symptoms: Myalgia, Pyrexia
Clinical narrative: High temp muscle aches
Age: 1.0
Sex: U
Vaccine: HEPA
Symptoms: No adverse event, Product storage error
Clinical narrative: No additional AE details were provided and no additional AE's were reported; patients that were administered vaccines after they were involved in a TE.; This spontaneous report was received from a licensed practical nurse and referred to a 1-year-old patient of unspecified gender. The patient's medical history, concurrent conditions, concomitant therapies were not reported.  On 07-NOV-2022 at 11:10, the patient was vaccinated with hepatitis a vaccine, inactivated (VAQTA), 0.5 milliliter intramuscular injection, 0.5 milliliter, lot #U038841, expiration date: 06-MAR-2023, administered intramuscularly for prophylaxis in left thigh after the vaccine was involved in a temperature excursion (Product storage error). The storage temperature of the hepatitis a vaccine, inactivated (VAQTA) was 11.4 degrees Celsius for a time frame of 1 hour 30 minutes. There was no previous temperature excursion. No additional adverse effect (AE) details were provided (no adverse event).  This is one of 9 reports received from the same reporter. ; Sender's Comments:  US-009507513-2212USA000031: US-009507513-2212USA000032: US-009507513-2212USA000033: US-009507513-2212USA000034: US-009507513-2212USA000035: US-009507513-2212USA000036: US-009507513-2212USA000037: US-009507513-2212USA000038:
Sex: U
Vaccine: MMR, UNK
Symptoms: Incorrect route of product administration, No adverse event
Clinical narrative: No additional adverse events; MMR II vaccine via intramuscular route; This spontaneous report was received from a pharmacist concerning a patient of unknown age and gender.  The patient's medical history, concurrent conditions and concomitant therapies were not reported.   On 20-OCT-2022, the patient was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (rHA) (M-M-R II) subcutaneous injection, 1 dose, lot #U006488, expiration date: 26-FEB-2023, administered intramuscularly as prophylaxis (strength was not provided); in combination with sterile diluent (strength, lot #, expiry date, route of administration, and indication were not provided) (Subcutaneous injection formulation administered by other route). No additional adverse events were reported.
Age: 0.17
Sex: M
Vaccine: PNC13, PPV
Symptoms: No adverse event, Product administered to patient of inappropriate age, Wrong product administered
Clinical narrative: no adverse effect; Medical assistant reporting an AE for PNEUMOVAX23. Caller reports that on 11/21/2022 a dose of PNEUMOVAX23 was inadvertently administered to a patient who was 2 months old. AE filed for misuse. Caller states the patient was meant to receive PCV-13 va; Wrong vaccine administered; This spontaneous report was received from a medical assistant referring to a 2-month-old male patient. The patient's medical histories, concomitant medications, concurrent conditions and historical therapies were not reported.  On 21-NOV-2022, the patient was inadvertently vaccinated with a dose of pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) injection (0.5 mL, product quantity:1, lot #W019639, expiration date: 06-MAY-2024, administered intramuscularly in left thigh) for prophylaxis (product administered to patient of inappropriate age) at private doctor's office/hospital. This was initial use of this vaccine. It was reported that the patient was meant to receive pneumococcal vaccine conj 13v (crm197) (PREVENAR 13) (wrong product administered). The operator was a trained healthcare professional. No adverse event was reported at the time of reporting.  Error was identified and reported to doctor, health department and manufacturer. There was no treatment for the patient.
Sex: U
Vaccine: MMRV, VARCEL
Symptoms: No adverse event, Overdose
Clinical narrative: No additional AE information available; a patient was given both PROQUAD and VARIVAX concomitantly.; This spontaneous report was received from a medical assistant and referred to a patient of unspecified age or gender. The patient's medical history and concurrent condition were not reported. Concomitant medication included sterile diluent.   On 07-DEC-2022, the patient was given both measles, mumps, rubella and varicella (oka-merck) virus vaccine live (rHA) (PROQUAD) subcutaneous injection, lot #W019631, expiration date: 19-DEC-2023 for prophylaxis (strength, dose, route of administration were not provided); and  varicella virus vaccine live (oka/merck) (VARIVAX) subcutaneous injection, lot #W021743, expiration date: 10-JUL-2024 for prophylaxis (strength, dose, route of administration were not provided) concomitantly (overdose). The sterile diluent used to reconstitute both products was from the same lot #W007177, expiration date: 10-OCT-2024. No additional adverse events information available.
Sex: M
Vaccine: HPV9
Symptoms: Expired product administered, No adverse event
Clinical narrative: HCP reporting she administered GARDASIL 9 to a patient that was 12 days expired.; No additional AE.; This spontaneous report was received from a nurse and refers to a currently 40-year-old male patient. There was no information about the patient's concomitant therapies, drug reactions, allergies or medical history provided  On an unknown date, the patient was vaccinated with 12 days expired hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) as prophylaxis (dose, dose number, lot #, expiry date, route of administration and anatomical location were not provided) (expired vaccine used). The nurse was inquiring if the dose was valid or needed repeated and was informed that without an expiration date and date of administration, information regarding the validity of the product could not be provided. No additional adverse event (AE) was reported.
Sex: U
Vaccine: HPV9
Symptoms: Expired product administered
Clinical narrative: No additional AE; Caller reporting GARDASIL 9 was administered after expiration.; This spontaneous report has been received from a medical assistant concerning a patient of unknown age and gender. The patient's medical history, drug reactions or allergies, concurrent conditions and concomitant medications were not reported.  On 15-DEC-2022, the patient was vaccinated with an expired dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) 0.5 ml, lot # T025369, expiration date: 01-DEC-2022 (route of administration and anatomical location were not provided) for prophylaxis (expired product administered). No previous temperature excursion were reported. No additional events were reported.
Sex: M
Vaccine: MMR
Symptoms: Learning disability, Seizure, Syncope
Clinical narrative: went on to develop a learning disablity; seizure; This spontaneous report as received from a mother concerning her 1-year-old son, during an interview. There was no information about the patient's medical history, concurrent conditions or concomitant medication.  In 2007, the patient was vaccinated with a dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) (dose, dose number, route of administration, anatomical location, lot number and expiration date were not reported) for prophylaxis.       On an unknown date in 2007, the patient ended up having a seizure, and had to go to the ER two separate times, on an unspecified date. After the first visit he was sent home, and then they had to go back to the ER. Eventually the son recovered (date unspecified) but went on to develop a learn (learning disability), on an unknown date.  The outcome of seizure was reported as recovered, on an unknown date and the outcome of develop a learn (learning disability) was unknown.   The reporter considered seizure and learning disability to be related to Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II).  Causality of the event of develop a learn (learning disability) with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II)  was unspecified.  Upon internal review, the event of syncope was considered to be medically significant.
Age: 4.0
Sex: M
Vaccine: MMRV
Symptoms: Incorrect route of product administration, No adverse event
Clinical narrative: no additional AEs; CMA calling to report that PROQUAD was administered via IM route to 4 year old patient on 12/16/22. No further information provided, no additional AEs, no PQCs.; This spontaneous report has been received from a medical assistant referring to a 4-year-old male patient.   The patient's pertinent medical history, drugs reactions or allergies and concomitant medications were not provided.  On 16-DEC-2022, the patient was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live recombinant Human albumin (rHA) (PROQUAD) subcutaneous injection, 0.5 ml once (strength, dose, units, vaccination scheme, frequency, route of administration and anatomical site of injection were not provided), lot number W028564 has been verified to be a valid lot number with expiration date on 06-MAR-2024, administered as prophylaxis via Intramuscular instead of subcutaneous (subcutaneous injection formulation administered by other route). No additional adverse event was provided.
Sex: U
Vaccine: VARZOS
Symptoms: Herpes zoster, Ill-defined disorder
Clinical narrative: Subsequent to Plaintiff's ZOSTAVAX inoculation, Plaintiff was treated (...) for shingles and other zoster-related conditions.; Subsequent to Plaintiff's ZOSTAVAX inoculation, Plaintiff was treated (...) for shingles and other zoster-related conditions.; Information has been received from a lawyer regarding a case in litigation concerning a patient (pt) of unknown age and gender. The pt's medical history, concurrent conditions and concomitant medications were not provided. On or about 01-OCT-2012, the pt was inoculated with a dose of zoster vaccine live (ZOSTAVAX) (exact dose, strength, dose number, lot #, expiration date, site and route of administration were not provided) as prescribed and/or administered by a pharmacist at a pharmacy for the long-term prevention of shingles and zoster-related conditions. On an unknown date, subsequent to the pt's inoculation with zoster vaccine live (ZOSTAVAX), the pt was treated by a physician for shingles and other zoster-related conditions. As a direct and proximate result of the pt's use of the zoster vaccine live (ZOSTAVAX) vaccine, the pt had and would continue suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs included care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; and other losses and damages; and would continue to suffer such losses, and damages in the future. The outcome of the events was considered to be not recovered. The reporter considered the events to be related to zoster vaccine live (ZOSTAVAX).
Sex: F
Vaccine: VARZOS, VARZOS, VARZOS
Symptoms: Extra dose administered, Herpes zoster, Pain, Vaccination failure
Clinical narrative: Had three shots, had them (shingles)/Suspected vaccination failure; Shingles/ Had three shots, had them (shingles); Pain is not as bad; Had three shots; This case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a female patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Co-suspect products included Herpes zoster (Shingles vaccine) for prophylaxis and Herpes zoster (Shingles vaccine) for prophylaxis.   The patient's past medical history included shingles (had shingles three times in the same place) and pain.   On an unknown date, the patient received the 3rd dose of Shingles vaccine, the 2nd dose of Shingles vaccine and the 1st dose of Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, Shingles vaccine and Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant), shingles, pain and extra dose administered. On an unknown date, the outcome of the vaccination failure, shingles, pain and extra dose administered were unknown.   The reporter considered the vaccination failure, shingles and pain to be related to Shingles vaccine, Shingles vaccine and Shingles vaccine.     Additional Information: GSK receipt date: 17-Dec-2022 Reporter's comment: The case was received from the patient via interactive digital media. The patient had shingles three times in the same place.  The first time, did not knew what it was but it was very painful, had three shots, had them in the same place every time, but the pain was not as bad. Additional supportive information: The patient received 3 shots, which led to extra dose administered. This case was considered as suspected vaccination failure since the details regarding the time to onset and laboratory confirmation of shingles were unknown at the time of reporting. The follow-up could not be possible as no contact details were available.
Sex: F
Vaccine: VARZOS
Symptoms: Extra dose administered
Clinical narrative: just got one dose , unknown if was 2nd or 3rd; This case was reported by a consumer via interactive digital media and described the occurrence of extra dose administered in a 73-year-old female patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received the 3rd dose of Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced extra dose administered. On an unknown date, the outcome of the extra dose administered was unknown.   Additional Information: GSK Receipt Date: 13-DEC-2022 Reporter's Comment: This case was reported by a patient via interactive digital media. The patient just got a Shingles shot. The patient was not sure if she had 2nd or if this was the 3rd dose. Additional Supportive Information: The patient received 3rd Shingles vaccine, which led to extra dose administered. The follow-up could not be possible as no contact details were available. On conservative basis the case was kept valid for the 3rd dose.
Sex: U
Vaccine: VARZOS
Symptoms: Incomplete course of vaccination
Clinical narrative: Can't determine if I had the 2nd dose; This case was reported by a consumer and described the occurrence of incomplete course of vaccination in a patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose in 2021).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK receipt date: 15-Dec-2022 Reporter's comment: The patient know he/she had at least 1 shingrix vaccine in 2021 but could not determine if he/she had the second dose. The patient asked that it was safe to start over with the series now since it was possible he/she had both the vaccine. Additional supportive information: Till the time of reporting, the patient did not receive the second dose of Shingrix, which led to incomplete course of vaccination.